Emilumenib
Emilumenib (Menin-MLL inhibitor 26) is an orally active Menin-MLL inhibitor. Emilumenib also is an active reference. Emilumenib can inhibits cell growth. Emilumenib can be used for the research of leukemia[1].
Product Specifications
CAS Number
[2440018-29-9]
Product Name Alternative
DS-1594a; Menin-MLL inhibitor 26
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/emilumenib.html
Purity
96.22
Solubility
DMSO : 41.67 mg/mL (ultrasonic; warming)
Smiles
CN([C@H]1C[C@H](C[C@H]1O)NCC2=CC=C(C3=CC(OC)=C(N=N3)OC)C=C2)C4=C5C(SC(CC(F)(F)F)=C5)=NC=N4
Molecular Formula
C27H29F3N6O3S
Molecular Weight
574.62
References & Citations
[1]Cycloalkane-1, 3-diamine derivatives, et al. Cycloalkane-1, 3-diamine derivatives. Patent. CN113164481A.|[2]Numata M, et al., A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1. Cancer Cell Int. 2023 Feb 25;23 (1) :36.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6325074-01 0.2 mL
NFKBIB, CT (NFKBIB, IKBB, TRIP9, NF-kappa-B inhibitor beta, I-kappa-B-beta, Thyroid receptor-interacting protein 9) (Azide free) (HRP)
Ask
View Details MBS6325074-02 5x 0.2 mL
NFKBIB, CT (NFKBIB, IKBB, TRIP9, NF-kappa-B inhibitor beta, I-kappa-B-beta, Thyroid receptor-interacting protein 9) (Azide free) (HRP)
Ask
View Details